![]()
To produce an efficacy rate for the vaccine, an external and independent data monitoring committee (DMC) performed its first interim analysis after 94 participants in the 44,000-volunteer trial developed COVID-19.
It found that 90% of the people who received the vaccine were better protected from COVID-19 than the people who did not receive it (but had received placebos).
“Today is a great day for science and humanity. The first set of results from our Phase Three COVID-19 vaccine trial…
Post comments (0)